Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biofrontera Inc (NQ: BFRI )

3.790 +0.580 (+18.07%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biofrontera Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Biofrontera's Return On Capital Employed Overview
Via Benzinga
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
Via ACCESSWIRE
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
Via ACCESSWIRE
Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
From Biofrontera Inc.
Via GlobeNewswire
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
From Biofrontera Inc.
Via GlobeNewswire
Why ObsEva Shares Are Trading Higher By Over 70%; Here Are 21 Stocks Moving Premarket
Gainers ObsEva SA (NASDAQ: OBSV) shares rose 71.9% to $0.2848 in pre-market trading after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million. 
Via Benzinga
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
From Biofrontera Inc.
Via GlobeNewswire
Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update
From Biofrontera Inc.
Via GlobeNewswire
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
From Biofrontera Inc.
Via GlobeNewswire
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG
From Biofrontera Inc.
Via GlobeNewswire
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
From Biofrontera Inc.
Via GlobeNewswire
Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
From Biofrontera Inc.
Via GlobeNewswire
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference
From Biofrontera Inc.
Via GlobeNewswire
Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
From Biofrontera Inc.
Via GlobeNewswire
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
From Biofrontera Inc.
Via GlobeNewswire
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
From Biofrontera Inc.
Via GlobeNewswire
Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022
From Biofrontera Inc.
Via GlobeNewswire
Global Laser Therapy Devices Billion Dollar Market Thriving on Growing Demand
Palm Beach, FL – October 4, 2022 – FinancialNewsMedia.com News Commentary – The laser therapy market has been having a very health growth trend in recent years and is expected to continue through the... 
Via FinancialNewsMedia
Topics Death Economy
Exposures Death Economy
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
From Biofrontera Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
Via InvestorPlace
Biofrontera's Return On Capital Employed Overview
Benzinga Pro data, Biofrontera (NASDAQ:BFRI) reported Q2 sales of $4.46 million. Earnings fell to a loss of $850 thousand, resulting in a 115.29% decrease from last quarter. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 37 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 31 companies hit new 52-week lows. 
Via Benzinga
Earnings Scheduled For August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.